| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Rosalio Madrigal
Jenna Brashear
Rosalio Madrigal
Michael Rose
| Share Statistics | LGND | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $5,980.9 | $409.9 | 71% |
|
| Shares Out (Mil) | 20.0 | 44.5 | 30% |
|
| Institutional Ownership | 98.1% | 81.1% | 77% |
|
| Float (Mil) | 19.6 | 45.7 | 28% |
|
| Beta | 1.01 | 0.72 | 61% |
|
| Avg Daily Volume (000s) | 251 | 284 | 48% |
|
| Price Change (52-week) |
57.8% | 52.7% | 89% |
|
| Growth | LGND | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 10.4% | 5.7% | 60% |
|
| Net Income (5yr) | 112.7% | (2.0%) | 99% |
|
| EPS (5yr) | 104.8% | 14.9% | 99 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 40.8% | (15.1%) | 91% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 10 | 10 | |
| Current EPS | $2.866 | $9.491 | $12.206 | |
| Month Ago EPS | $2.991 | $9.305 | $11.950 | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | $3.166 | $9.288 | $11.915 | |
| Year/Year Chg | (300.4%) | 54.8% | 138.7% | |
| Financials | LGND | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $254 | $326 | 34% |
|
| Net Income (TTM) (Mil) | $52 | ($11) | 55% |
|
| EPS (TTM) | $2.600 | ($0.600) | 75% |
|
| Operating Cash Flow (TTM) (Mil) | $91 | ($6) | 51% |
|
| Net Cash Flow (TTM) (Mil) | ($36) | $2 | 23% |
|
| Long-Term Debt (Q1) (Mil) | $701 | $6 | 62% |
|
| Enterprise Value (Q1) (Mil) | $7,163 | $466 | 68% |
|
| Valuation | LGND | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.22 | 1.96 | 85% |
|
| P/E | 125.1 | 20.1 | 96% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 1.7 | 1.2 | 65% |
|
| Ratios | LGND | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 86.1% | 67.7% | 92% |
|
| Net Margin | 20.3% | 3.4% | 79% |
|
| ROA | 2.8% | (21.5%) | 60% |
|
| ROE | 5.4% | (21.0%) | 44% |
|
| Liabilities to Assets | 57.0% | 31.8% | 50% |
|
| F-Score | 4 | 3 | 33% |
|
Ligand Pharmaceuticals Incorporated did not pass any screens on 11/5/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
